SCHEDULE 13G: Alyeska Investment Group Discloses 9.99% Passive Stake in Aligos Therapeutics

Alyeska Investment Group, L.P., along with Alyeska Fund GP, LLC and Anand Parekh, has reported a 9.99% beneficial ownership stake in Aligos Therapeutics, Inc. as of March 31, 2025, primarily for passive investment purposes.

Summary

• The reporting persons are Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh.
• The filing pertains to their beneficial ownership of Common Stock, par value $0.0001 per share, of Aligos Therapeutics, Inc.
• As of March 31, 2025, the aggregate amount beneficially owned by each reporting person is 530,000 shares.
• This beneficial ownership represents 9.99% of the class of Aligos Therapeutics, Inc. Common Stock.
• The ownership includes 412,000 shares of Common Stock and 118,000 shares exercisable from warrants, which are limited by a 9.99% ownership cap as per their terms.
• The percentage calculation is based on 5,314,311 outstanding shares of Common Stock of Aligos Therapeutics, Inc., as reported in the Issuer's Form DEF 14A filed on April 28, 2025.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: Neutral, as this is a factual regulatory filing disclosing beneficial ownership, not a performance or strategic update.

Positives

• A significant institutional investor, Alyeska Investment Group, L.P., has disclosed a substantial stake in Aligos Therapeutics, Inc., indicating potential confidence in the company.

Negatives

• The beneficial ownership from warrants is capped at 9.99% of the outstanding shares, limiting the immediate full exercise of all warrants held by the reporting persons.

Risks

• No specific risks related to the issuer's operations or financial health are disclosed in this ownership filing, as it is a compliance document.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding the issuer's future performance or strategic outlook.

Management Comments

• The reporting persons certify that the securities referred to were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing reflects an institutional investor's passive stake in a biotechnology company, a common occurrence in the sector as funds take positions in publicly traded firms based on their investment strategies.

Comparison to Industry Standards

• Not applicable, as this document is a regulatory ownership disclosure and does not contain performance metrics for comparison against industry standards or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which may influence market perception and investor confidence.

Next Steps

• Ongoing compliance with SEC reporting requirements for beneficial ownership by the reporting persons.

Key Dates

Keywords

Aligos Therapeutics, Alyeska Investment Group, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, SEC filing